Dexcom G8 CGM: release timeline, expectations and what comes next

Dexcom’s Investor Day offered the clearest look yet at what the company has planned beyond G7.

While the race is on to integrate the use of AI in medtech products, and this is certainly reflected in Dexcom’s strategy, for users the simpler questions are: when is G8 coming, and what will actually be different?

Key takeaways

• G8 sensor will be 50% smaller than G7
• 15-day wear
• New squarer design with rounded corners
• New sensing platform with adaptive algorithm
• Future multi-analyte sensing could include ketones and potassium
• Launch looks most likely from 2027
• Built for Dexcom’s wider AI and biosensing future

Dexcom G8 at a glance

Feature	Dexcom G7	Dexcom G8 (expected)
Wear time	10 days / 15-day US variant	15 days
Size	current	50% smaller
Shape	oval / rounded	squarer rounded profile
Algorithm	current	adaptive
Multi-analyte	no	in future plans
Ketones	no	potential
Potassium	no	in development

How much smaller will Dexcom’s G8 be?

Dexcom says G8 will be 50% smaller than G7, making it a significant physical redesign. Interestingly, Dexcom are not (yet) stating if it will be smaller than a FreeStyle Libre sensor, or be the smallest on the market.

But, images revealed by Dexcom doshow that the sensor is changing shape. The form of a G8 will be more geometrically balanced with a squarer design and rounded corners.

This is likely to be welcomed by CGM wearers as a lower-profile, squarer design could mean better wearability under clothing, less snagging on sleeves or straps, improved comfort during sleep, and a more polished wearable-tech feel.

Will Dexcom G8 have 15-day wear?

One of the most meaningful expected upgrades with G8 is wear duration.

Dexcom’s presentation points toward 15-day wear becoming standard, extending beyond the current 10-day G7 experience available in many countries and bringing Dexcom into closer direct competition with FreeStyle Libre.

For many users, that could mean fewer sensor changes, fewer insertions and smoother glucose data continuity.

A popular feature of the existing G7 is the 12-hour grace period at the end of sensor life, giving users extra flexibility to change sensors without an abrupt cutoff in readings. The US-only Dexcom G7 15 Day version follows the same principle, offering up to 15 days plus a 12-hour grace period, effectively taking total wear time to 15.5 days. Our Dexcom G7 review  explores how the current platform performs in real-world use.

For real-life users, grace periods can make a genuine difference to day-to-day management. Sensor changes do not always happen at the perfect moment. A grace period can reduce pressure if a sensor expires overnight, during work, while travelling, or simply when it is inconvenient to switch immediately.

If Dexcom carries this same approach into G8, the real-world benefit could extend beyond the headline 15-day claim.

But headline wear time only matters if the sensor consistently gets there in daily use.

That remains the real test.

Could Dexcom G8 measure ketones?

Potentially, yes.

One of the more intriguing signals from Dexcom’s investor presentation is its move toward multi-analyte sensing, suggesting future platforms could monitor more than glucose alone.

For diabetes users, ketones are the most obvious and genuinely meaningful next step.

That would be particularly relevant around illness, pump failures or suspected DKA, where ketone testing currently remains separate from the wearable CGM experience.

Dexcom is not alone here.

Abbott has already indicated that future FreeStyle Libre development includes ketone capability, making this one of the clearest next battlegrounds in diabetes medtech.

The real question is which company gets there first with something clinically useful.

Why did Dexcom mention potassium?

Potassium was one of the more unexpected details in Dexcom’s roadmap.

It is not something most CGM users think about routinely, but it becomes clinically relevant during DKA and broader metabolic instability.

That does not mean G8 is about to become a consumer potassium tracker.

The bigger message is strategic.

Dexcom is signalling that it increasingly sees itself as a broader biosensing business rather than simply a glucose company.

Potassium is less about near-term functionality and more about how far the platform could eventually evolve.

New sensing platform and adaptive algorithm

Beyond the obvious physical redesign, Dexcom also signalled that G8 is being built on a new sensing platform, rather than simply acting as a smaller version of G7.

That matters because it suggests more than cosmetic change.

Dexcom also referenced an adaptive algorithm, which points toward smarter sensor interpretation and potentially more consistent performance over longer wear.

Exactly how that translates into real-world experience remains unclear.

But for users who have experienced signal interruptions, early failures or inconsistent readings, algorithm performance may matter just as much as hardware.

How does this compare with Abbott’s plans for FreeStyle Libre?

Dexcom’s G8 roadmap makes clear that the company is thinking beyond a routine sensor upgrade. But it is not alone.

Abbott’s strategy increasingly points in a similar direction, but through a slightly different route, with Libre Assist, broader integration ambitions, and expansion into consumer metabolic health. We explored what Libre Assist could mean for FreeStyle Libre users here.

In the US, Abbott increasingly presents the platform more simply as Libre, including the diabetes app used by existing sensor users, rather than consistently using the full FreeStyle Libre branding more familiar in markets like the UK and Europe. That subtle shift matters because it reflects a broader move toward simpler consumer-facing platform branding, rather than a product identity tied solely to traditional diabetes hardware.

Strategically, both companies are clearly moving in the same direction.

Dexcom’s headline G8 upgrades focus on a 50% smaller sensor, 15-day wear, a redesigned form factor and a new sensing platform, but the longer-term ambition appears much bigger, with multi-analyte sensing that could eventually include ketones and other biomarkers.

Abbott appears to be building toward a similar future.

Future FreeStyle Libre development is expected to include ketone sensing, making this one of the clearest next competitive battlegrounds between the two biggest CGM players.

Where the two companies may differ is emphasis.

Dexcom’s Investor Day messaging leaned heavily into connected biosensing, adaptive algorithms, predictive intelligence and wider AI-led ecosystem development. The G8 story feels as much about software and platform evolution as hardware.

Abbott’s strategy increasingly points in a similar direction, but through a slightly different route, with Libre Assist, broader integration ambitions, and expansion into consumer metabolic health through platforms such as Lingo by Abbott.

In practical terms, Dexcom and Abbott increasingly look less like companies pursuing separate futures and more like two rivals converging on the same destination.

The next CGM competition may no longer be about who offers the smallest sensor or the longest wear time.

It may increasingly be about who delivers useful ketone integration first, whose ecosystem feels most dependable, and who best balances diabetes-specific needs with broader health ambitions.

What CGM users care about	Dexcom G8 (expected)	Abbott / FreeStyle Libre direction
Sensor size	50% smaller than G7	Libre 3 already among the smallest current CGM sensors
Wear time	15 days expected (+ likely grace period if Dexcom keeps current model)	FreeStyle Libre 2 Plus already offers 15-day wear
Shape / wearability	New squarer design with rounded corners	Current Libre sensors already ultra-low profile
Ketone monitoring	Future multi-analyte roadmap includes ketones	Abbott has already signalled ketone capability in future Libre development
Beyond glucose	Potassium mentioned as future biosensing ambition	Abbott focusing on broader metabolic tracking via Lingo by Abbott
AI / smarter support	Adaptive algorithm + wider AI ecosystem ambitions	Libre Assist and broader connected platform development
Consumer health ambitions	Moving beyond traditional diabetes-only positioning	Already expanding beyond diabetes throughLingo by Abbott
Ecosystem strategy	Dexcom building broader biosensing platform	Abbott increasingly positioning Libre as a wider health platform

When is Dexcom G8 expected to launch?

Dexcom has not yet confirmed a launch date for G8, but based on statements from the CEO, Jake Leach, this is clearly a future platform rather than an imminent release.

A realistic expectation is continued G7 expansion through 2026 and the Inverstors' presentation identified these countries as priority: Canada, Japan, France, Germany, South Korea, Italy, Saudi Arabia, United Kingdom, Spain and Australia.

G8 is likely to launch in the US from 2027 onwards, depending on regulatory progress ie. FDA approval in the US. So while G8 now feels tangible, it is not close.

Will Dexcom G8 launch in my country?

The usual pattern for Dexcom, and diabetes medtech companies more broadly, is a phased rollout rather than a worldwide day-one launch. The US typically comes first, followed by other markets as regulatory approvals, reimbursement decisions and commercial priorities progress.

Canada often follows relatively soon after US launches, although timelines can still vary. European access is usually more fragmented, with rollout differing between countries depending on approval pathways, healthcare systems and reimbursement arrangements. Australia and New Zealand can take longer again, particularly where public funding assessments or additional regulatory processes are involved.

In practical terms, that means readers in the US may well see G8 first, while those in Europe, Canada, Australia or New Zealand could be hearing about the product for some time before it becomes locally available.

What comes after G8?

This may actually be the biggest story.

Because Investor Day suggests G8 is not the destination. It is the platform.

Dexcom’s roadmap increasingly points toward multi-analyte sensing, predictive alerts, AI-driven interpretation, broader biosensing and connected health ecosystems.

That means G8 is not simply another sensor refresh. It is infrastructure for a much broader future strategy.

The competition between Dexcom and Abbott increasingly looks less like a simple hardware battle and more like a race to build the most useful connected biosensing ecosystem.

That may be the bigger story than G8 itself.

Disclaimer

Details are correct to the best of the author’s knowledge at the time of writing. Information may vary by region and over time. Always check with the manufacturer or your healthcare provider.

Love My Libre is not affiliated with Dexcom or Abbott. This content is not medical advice.